Lacerta Therapeutics
  • Home
  • About
  • Programs & Pipeline
    • Lysosomal Storage Disease
    • Ataxias
    • Neuro-Oncology
  • Science & Technology
    • AAV CAPSID
    • AAV VECTOR
  • News
  • Careers
  • Contact Us
Select Page

EDGAR RODRIGUEZ, PHD

by lacerta2022 | Sep 16, 2023

About Lacerta

Lacerta has quickly become a nationally recognized partner in the development of genetic-based medicines & treatments for central nervous system and lysosomal storage diseases.

Recent Posts

  • Concept Companies Leads Development Efforts on Second Phase for Lacerta Therapeutics in Alachua’s Progress District
  • Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders
  • Tech Tuesday: Gene Therapy

About Lacerta
Our Commitment
Our Team
Board of Directors
Scientific Advisors
Collaborations

Programs & Pipelines

Lysosomal
Ataxias
Neuro-Oncology

Our Commitment

Patient Advocacy
Patient Resources

Science & Technology

AAV Capsid
AAV Vector

News

News & Updates

Careers

Open Positions
Our Culture

Contact Information

Headquarters
Lacerta Therapeutics, Inc.
14189 NW 129th Way
Alachua, FL 32615


(386) 518-6424



info@lacertatx.com

  • Follow
Copyright 2024 | Lacerta Therapeutics | Built and Powered by XWeb Pros
  • Terms and Conditions
  • |
  • Privacy Policy
Copyright2024 | Lacerta Therapeutics | Built and Powered by XWeb Pros
Terms and Conditions
Privacy Policy